BSE Live
Jan 30, 16:01Prev. Close
1208.45
Open Price
1198.60
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 30, 15:59Prev. Close
1208.90
Open Price
1200.00
Bid Price (Qty.)
1218.10 (63)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Dr Reddys Laboratories (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 618.30 | -656.40 | 544.96 | 1,239.90 | 201.34 | |
| Net CashFlow From Operating Activities | 1,851.00 | 599.10 | 512.77 | 1,258.90 | 110.50 | |
| Net Cash Used In Investing Activities | -1,246.20 | -505.00 | -809.79 | -414.87 | -2,761.38 | |
| Net Cash Used From Financing Activities | -531.70 | -265.10 | -775.40 | 23.31 | 2,688.43 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 73.10 | -171.00 | -1,072.42 | 867.34 | 37.55 | |
| Cash And Cash Equivalents Begin of Year | 586.90 | 733.30 | 1,817.71 | 993.67 | 942.07 | |
| Cash And Cash Equivalents End Of Year | 660.00 | 562.30 | 745.29 | 1,861.01 | 979.62 |
22.01.2026
Dr Reddys Labs Consolidated December 2025 Net Sales at Rs 8,753.40 crore, up 4.44% Y-o-Y
22.01.2026
Dr Reddys Labs Standalone December 2025 Net Sales at Rs 4,282.70 crore, down 14.6% Y-o-Y
22.01.2026
16.01.2026
22.01.2026
Dr Reddys Labs Consolidated December 2025 Net Sales at Rs 8,753.40 crore, up 4.44% Y-o-Y
22.01.2026
Dr Reddys Labs Standalone December 2025 Net Sales at Rs 4,282.70 crore, down 14.6% Y-o-Y
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz